Natick, MA-based medical devices maker Boston Scientific has expanded its cardiovascular products business with the purchase of Atritech, a Plymouth, MN, developer of a device alternative to treating patients with atrial fibrillation who are at risk of stroke, the company says today. Boston Scientific (NYSE:[[ticker:BSX]]) is paying $100 million upfront for Atritech as up to $275 million in regulatory and commercial milestone fees through 2015, according to Boston Scientific. Atritech’s device is cleared for sale in Europe and but is still in development for the U.S. market.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
